SC-2004 is our lead oral GLP-1R agonist, developed using our proprietary method of fine-tuned receptor modulation.
Treated animals have shown an average weight loss of 16% after just 2 weeks of daily dosing along with a significant reduction in food intake and normalization of hyperglycemia.
Most importantly, the molecule is safe and well tolerated with no adverse side effects observed.
SC-2004 represents our efforts to develop a widely available, easily manufactured oral therapeutic that maintains the therapeutic benefits of GLP-1 receptor modulation with enhanced tolerability, safety, convenience, and broad efficacy.
SC-2004: small molecule GLP-1R agonist
SC-1012 is a novel small molecule targeting an under-explored pathway for metabolic syndrome.
These orally available small molecules are effective at improving function and viability of human pancreatic β-cells from donors including stimulation of insulin secretion and protection from inflammatory cytokines.
Currently in optimization stage, we expect to nominate clinical candidates in 12-18 months.